19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02583672
(ClinicalTrials.gov)
September 201521/8/2015Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory MedicationsGaucher Disease Type 1Drug: N-acetylcysteineUniversity of MinnesotaRare Diseases Clinical Research Network;National Center for Advancing Translational Sciences (NCATS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Neurological Disorders and Stroke (NINDS);Lysosomal Disease NetworkRecruiting18 YearsN/AAll50Phase 2United States
2NCT01427517
(ClinicalTrials.gov)
July 201130/8/2011Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseIntravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseParkinson's Disease;Gaucher's DiseaseDrug: N-acetylcysteineUniversity of MinnesotaRare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS);National Institute of Neurological Disorders and Stroke (NINDS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 YearsN/AAll9Phase 1United States
3NCT00028262
(ClinicalTrials.gov)
February 200117/12/2001Cystagon to Treat Infantile Neuronal Ceroid LipofuscinosisA Combination Therapy With Cystagon and N-Acetylcysteine for INCL PatientsInfantile Neronal Ceroid LipofuscinosisDrug: CystagonEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompleted6 Months3 YearsAll10Phase 4United States